Merck在发放Evaxion的实验性细菌疫苗许可证前支付7.5M美元, Merck pays $7.5M upfront to license Evaxion’s experimental bacterial vaccine, with up to $600M more in potential payments.

Evaxion向Merck & Co.公司颁发了其临床前EVX-B3疫苗候选人许可证,其交易价值高达6亿美元,包括一笔750万美元的预付付款和与发展、批准和销售相关的潜在里程碑付款,加上使用费。 Evaxion has licensed its preclinical EVX-B3 vaccine candidate to Merck & Co. under a deal worth up to $600 million, including a $7.5 million upfront payment and potential milestone payments tied to development, approval, and sales, plus royalties. Merck现在将资助未来所有的发展。 Merck will now fund all future development. 疫苗针对一种与严重、复发感染相关的细菌病原体。 The vaccine targets a bacterial pathogen linked to severe, recurring infections. 这种合作始于2023年,现已扩大到包括淋病候选人EVX-B2,预计将在2026年初作出许可证决定。 The collaboration, begun in 2023, has expanded to include EVX-B2, a gonorrhea candidate, with a licensing decision expected by early 2026. 该协议将Evaxion的现金跑道延长到2027年初,并反映了对其AI驱动平台的强大市场信心,提高了其在市场前贸易中的24%份额。 The deal extends Evaxion’s cash runway into early 2027 and reflects strong market confidence in its AI-driven platform, boosting its shares 24% in premarket trading.